Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Published
Journal Article
We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-gamma ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.
Full Text
Duke Authors
Cited Authors
- Hubby, B; Talarico, T; Maughan, M; Reap, EA; Berglund, P; Kamrud, KI; Copp, L; Lewis, W; Cecil, C; Norberg, P; Wagner, J; Watson, A; Negri, S; Burnett, BK; Graham, A; Smith, JF; Chulay, JD
Published Date
- November 23, 2007
Published In
Volume / Issue
- 25 / 48
Start / End Page
- 8180 - 8189
PubMed ID
- 17961878
Pubmed Central ID
- 17961878
International Standard Serial Number (ISSN)
- 0264-410X
Digital Object Identifier (DOI)
- 10.1016/j.vaccine.2007.09.038
Language
- eng
Conference Location
- Netherlands